Private research note
Primary-source documents
Loading company analysis...
Loading company analysis...
UnitedHealth is showing a meaningful earnings and medical-cost recovery across UnitedHealthcare and Optum, but membership contraction, regulation, and investigations remain central risks.
Keep researching
Merck leans heavily on its oncology franchise Keytruda while building out newer vaccine and animal health businesses ahead of patent expiration.
Amgen is a large biotech with a diversified portfolio spanning inflammation, oncology, and bone health, along with a growing obesity drug candidate.
Thermo Fisher Scientific supplies lab equipment, reagents, and services used broadly across pharmaceutical, biotech, academic, and industrial research.
Form 4 reports insider transactions. Schedule 13D and 13G filings report certain significant ownership positions. 13F reports institutional holdings when filed by an investment manager. Always open the original filing for context.
This is a data-generated overview, not a published Rithvik Chethan research rating. Figures use the latest usable company filing and may differ from vendor-calculated trailing metrics.
Annual values from SEC filings. Free cash flow is calculated as operating cash flow less capital expenditures.
Review the Earnings tab for the expected date and estimates.
8-K
EMA, RSI, MACD, volume, structure, and key levels update after a completed daily candle.
The overall score is a weighted research judgment covering business quality, fundamental strength, growth catalysts, valuation, technical condition, and downside risk. A high score does not eliminate risk, and a low score does not guarantee poor performance.
The rating combines business quality, fundamentals, growth, valuation, technicals, and risk. It is a research opinion, not a price target or prediction.
UnitedHealth Group operates two connected health-care platforms:
UnitedHealthcare earns premiums and service fees for arranging and financing care. Optum Health operates or supports provider groups and value-based care. Optum Insight sells software, analytics, consulting, and revenue-cycle services. Optum Rx manages pharmacy benefits and specialty prescriptions.
The integrated model creates scale, data, distribution, and opportunities to coordinate benefits, pharmacy, technology, and care. It also creates regulatory and conflict-of-interest concerns because the company participates in many parts of the health-care system.
Second-quarter revenue was $112.03 billion, approximately flat year over year. Earnings from operations increased to $7.99 billion from $5.15 billion, and net margin improved to 4.9% from 3.1%. GAAP EPS increased to $6.04 and adjusted EPS reached $6.38.
The medical care ratio improved to 86.7% from 89.4%. The result included $860 million of favorable prior-period reserve development, with most related to 2026 dates of service. Investors should separate genuine pricing and medical-management improvement from reserve timing.
UnitedHealthcare revenue was $86.0 billion and operating earnings improved to $3.9 billion from $2.1 billion. However, medical membership declined to 48.5 million, down 525,000 sequentially. Medicare Advantage membership has contracted by 965,000 since year end.
Optum revenue declined to $65.7 billion from $67.2 billion, but operating earnings increased to $4.0 billion from $3.1 billion and margin expanded to 6.2%. Optum Health improved despite serving fewer value-based-care patients, Optum Insight benefited from operational improvement and contract timing, and Optum Rx produced modest earnings growth.
Management raised full-year adjusted EPS guidance to $19.50 to $20.00, operating-earnings guidance above $25.45 billion, and operating cash-flow guidance to approximately $24 billion.
Cash generation is strong, but the insurance subsidiaries must maintain regulatory capital. Debt, acquisitions, legal exposures, and shareholder returns compete for holding-company cash.
Near $407 per share, UnitedHealth's equity value was approximately $370 billion. The stock traded near 30.7 times trailing earnings, but only about 20.6 times the midpoint of 2026 adjusted EPS guidance.
The forward adjusted multiple is reasonable if medical-cost improvement and updated guidance prove durable. The valuation is less attractive if favorable reserve development, portfolio actions, or temporary cost measures account for too much of the rebound. My view is reasonable recovery valuation with above-average uncertainty.
UnitedHealth's live panel recalculates its EMA ribbon, 200-day EMA, RSI, MACD, volume, ATR, support, resistance, and trend after every completed daily candle. Health insurers can gap on medical-cost updates, Medicare rates, legal news, regulation, and guidance.
The strongest setup requires price above the 50-day and 200-day averages, a positive EMA structure, and breakouts supported by stronger volume. Because policy and legal events can override technicals, position sizing should account for overnight gap risk.
The automated panel estimates fair value gaps, order blocks, breaks of structure, changes of character, and nearby liquidity zones using completed daily candles. These zones are technical references and do not predict regulatory, legal, or medical-cost events.
The main checkpoints are the medical care ratio, reserve development, membership, Medicare Advantage pricing, Optum Health margins, Optum Insight contracts, Optum Rx reform, cash flow, debt, investigations, and updated guidance.
Final view: UnitedHealth earns a moderately bullish 74 because pricing, medical-cost management, Optum improvement, cash flow, and raised guidance support a real recovery. Membership losses, reserve timing, Medicare funding, investigations, PBM reform, cybersecurity, and debt keep the risk discount elevated.
This website and its analysis are provided for educational and informational purposes only. Nothing on this site constitutes financial, investment, legal, or tax advice, or an offer to buy or sell any security. Market data is provided by Finnhub and other third-party sources and may be delayed, incomplete, or inaccurate. The author may hold positions in securities discussed, and opinions may change without notice. Past performance does not guarantee future results. Always conduct your own research and consult a qualified financial professional before making investment decisions.
Automatically refreshed from Finnhub. Open each source to evaluate how the development affects the thesis.
UnitedHealth Group (UNH) stock has risen about 40% since late March 2026, against close to 19% for the S&P 500. Read cold, that looks like a recovery nobody could have timed. It was not hidden. The company had said plainly, months before the shares turned, that it would give up members to rebuild margin.
Molina Healthcare's Medicaid recovery, Medicare duals growth and contract wins support a focused turnaround story, positioning it ahead of UnitedHealth.
UnitedHealth Group has seen its share price deliver mixed results in recent years, with shorter term gains sitting alongside a longer multi year decline. That uneven share price path puts the spotlight on a simple question for investors who follow UnitedHealth Group stock: whether the current valuation is backed up by its earnings power. Over the past 3 years the stock has declined 21.4%, which puts more weight on whether the earnings profile justifies where the shares trade today. Recent...
In the closing of the recent trading day, UnitedHealth Group (UNH) stood at $372.8, denoting a -1.26% move from the preceding trading day.
History begins when the upgraded snapshot records each completed trading day. New entries will accumulate automatically.
Recalculated automatically from daily market data. Values are cached for one hour and use the latest completed candle. Smart money zones are algorithmic estimates and should be confirmed on the chart.